Gene

SYK

spleen associated tyrosine kinase

Explore in graph →CI-GENE-00034334HGNC:11491 ENSG00000165025 NCBI 6850 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
SYK OVEREXPRESSION1
Paclitaxel	Malignant Ovarian Neoplasm	Predictive	D	Supports Resistance	3	accepted	EID752 Overexpression and high p-SYK/SYK ratio were associated with resistance to paclitaxel. Inhibition of SYK with R406 resensitized cell lines to paclitaxel. PMID 26096845 · Yu et al., 2015 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (38)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved38 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Endometrial Carcinoma MSI (MSK, Clin Cancer Res 2022) ucec_ccr_msk_2022	Endometrial Carcinoma	Ssm	15	181

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.
· Cancer Cell · 2015 · PMID 26096845 · validated civic_curation pubmed